Evidence map›Paper›PMID 42621866›Full record

ArticleGynecologic oncology reports2026

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.

Jordyn Silverstein, Oladunni Alomaja, Deandra Chatram, Maryam Hajiabbasi, Eliya Shachar, Chi-Hong Tseng, Shivani Thaker, Aditya Bardia, Beth Karlan, Andrea Wahner Hendrickson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jordyn SilversteinDivision of Hematology/Oncology, University of California, Los Angeles, CA, United States of America.
Oladunni AlomajaDavid Geffen School of Medicine, University of California, Los Angeles, CA, United States of America.
Deandra ChatramDepartment of Oncology, Mayo Clinic, Rochester, MN, United States of America.
Maryam HajiabbasiDivision of Hematology/Oncology, University of California, Los Angeles, CA, United States of America.
Eliya ShacharDepartment of Oncology, Mayo Clinic, Rochester, MN, United States of America.
Chi-Hong TsengDepartment of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, United States of America.
Shivani ThakerDivision of Hematology/Oncology, University of California, Los Angeles, CA, United States of America.
Aditya BardiaDivision of Hematology/Oncology, University of California, Los Angeles, CA, United States of America.
Beth KarlanDivision of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, United States of America.
Andrea Wahner HendricksonDepartment of Oncology, Mayo Clinic, Rochester, MN, United States of America.
Gottfried E KonecnyDivision of Hematology/Oncology, University of California, Los Angeles, CA, United States of America.

Funding

Patient-Centered Outcomes Research Training in Urologic and Gynecologic Cancers (PCORT UroGynCan)T32CA251072 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Beth Y. Karlan, MARK S. LITWIN · 2020 to 2026
$2.1M
NCI NIH HHS T32 CA251072
6 · The paper itself

Abstract

Conclusions: T-DXd demonstrated promising real-world clinical outcomes in OC and EC that mirror DESTINY-PanTumor02. Responses were observed across HER2 IHC expression levels (1+ to 3+), with highest rwRR among HER2 3+. Prior PARP inhibitor exposure was associated with significantly shorter PFS, warranting further exploration.

Indexed as

Antibody-drug conjugatesEndometrial cancerOvarian cancerReal-world outcomesTrastuzumab Deruxtecan

Identifiers

PMID42621866
PMCPMC13487597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.